Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Molecular Templates Inc (MTEM)
Molecular Templates Inc (MTEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,497
  • Shares Outstanding, K 5,374
  • Annual Sales, $ 19,750 K
  • Annual Income, $ -92,720 K
  • 60-Month Beta 1.19
  • Price/Sales 0.34
  • Price/Cash Flow N/A
  • Price/Book 3.05
Trade MTEM with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 58.31%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -2.10
  • Number of Estimates 1
  • High Estimate -2.10
  • Low Estimate -2.10
  • Prior Year -5.85
  • Growth Rate Est. (year over year) +64.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.40 +17.65%
on 02/05/24
4.10 -2.44%
on 02/21/24
+0.26 (+6.95%)
since 01/26/24
3-Month
3.26 +22.70%
on 12/18/23
5.37 -25.51%
on 11/28/23
-0.90 (-18.37%)
since 11/24/23
52-Week
3.26 +22.70%
on 12/18/23
9.56 -58.17%
on 03/10/23
-3.09 (-43.57%)
since 02/24/23

Most Recent Stories

More News
Will Molecular Templates Inc. (MTEM) Report Negative Q1 Earnings? What You Should Know

Molecular Templates Inc. (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MTEM : 4.00 (unch)
TBPH : 9.14 (+1.78%)
Stocks Set to Open Lower as Investors Await FOMC Minutes, Inflation Data

June S&P 500 futures (ESM23) are down -0.21%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.34% this morning as market participants assessed recent labor market data while awaiting the release...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
JPM : 183.13 (-0.47%)
WFC : 54.13 (+0.50%)
C : 55.85 (-0.14%)
PXD : 234.30 (+0.78%)
FRC : 3.51 (-43.30%)
SQ : 76.11 (-3.56%)
MTEM : 4.00 (unch)
NTAP : 87.87 (+0.54%)
RBBN : 3.08 (-0.96%)
Molecular Templates Inc. (MTEM) Reports Q4 Loss, Lags Revenue Estimates

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -56% and 63.99%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

MTEM : 4.00 (unch)
HTGM : 0.4800 (-20.00%)
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Lags Revenue Estimates

Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -8.33% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

FENC : 9.07 (+0.73%)
MTEM : 4.00 (unch)
Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 32% and 13.53%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

HRTX : 2.54 (-2.31%)
MTEM : 4.00 (unch)
Spectrum Pharmaceuticals (SPPI) Reports Q4 Loss, Tops Revenue Estimates

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 33.33% and 5.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

SPPI : 1.0300 (unch)
MTEM : 4.00 (unch)
OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 3.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

OPTN : 1.6600 (+6.41%)
MTEM : 4.00 (unch)
Molecular Templates Inc. (MTEM) Reports Q3 Loss, Tops Revenue Estimates

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of 8.33% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

MTEM : 4.00 (unch)
PLXP : 0.0207 (unch)
Acutus Medical, Inc. (AFIB) Reports Q3 Loss, Tops Revenue Estimates

Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of 13.25% and 3.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

AFIB : 0.2188 (unch)
MTEM : 4.00 (unch)
Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates

Stevanato (STVN) delivered earnings and revenue surprises of 7.69% and 0.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

STVN : 32.43 (+0.81%)
MTEM : 4.00 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Molecular Templates Inc. is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies for the treatment of cancers and other serious diseases. Molecular Templates Inc., formerly known as Threshold Pharmaceuticals Inc., is headquartered...

See More

Key Turning Points

3rd Resistance Point 4.37
2nd Resistance Point 4.23
1st Resistance Point 4.11
Last Price 4.00
1st Support Level 3.86
2nd Support Level 3.72
3rd Support Level 3.61

See More

52-Week High 9.56
Fibonacci 61.8% 7.15
Fibonacci 50% 6.41
Fibonacci 38.2% 5.67
Last Price 4.00
52-Week Low 3.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar